ProCE Banner Activity


Know Your ADCs: Nursing Perspectives on Antibody–Drug Conjugates Targeting TROP2 in Solid Tumors


Get up to date with this on-demand webcast from a live symposium developed for oncology nurse specialists focused on TROP2-targeted antibody–drug conjugates and the management of their associated adverse events. 

Nurses: 1.25 Nursing contact hours

Released: June 22, 2023

Expiration: June 21, 2024

No longer available for credit.



Elise Hitron

Elise Hitron, MSN, FNP-C

Nurse Practitioner
Phase I Clinical Trials at Winship Cancer Institute
Atlanta, Georgia

Srigowri Kota

Srigowri Kota, MSN, BA, APRN, AGNP-C, OCN

Nurse Practitioner
Department of Genitourinary Medical Oncology
Rutgers Cancer Institute of New Jersey
New Brunswick, New Jersey

Neelima Vidula

Neelima Vidula, MD

Assistant Professor of Medicine
Harvard Medical School
Attending Physician
Department of Medical Oncology
Massachusetts General Hospital
Boston, Massachusetts

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner


Supported by an educational grant from Gilead Sciences, Inc. 

Gilead Sciences, Inc.

Target Audience

This educational program is intended for oncology nurses, nurse practitioners, clinical nurse specialists, and other healthcare professionals who care for patients with solid tumors.

Program Learning Goal

The goal of this activity is to improve the knowledge, confidence, and competence of oncology nurses, nurse practitioners, and clinical nurse specialists to apply and explain available clinical data on novel and emerging therapies to individualize care for patients with solid tumors on or eligible for treatment with TROP2-targeted therapies.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Compare the unique mechanism of action between the antibody–drug conjugates sacituzumab govitecan and datopotamab deruxtecan to each other and cytotoxic chemotherapy

  • Evaluate individualized treatment strategies with ADCs targeting TROP2 for patients with breast cancer and NSCLC considering recent clinical data and approved indications

  • Explain to patients the role of TROP2-targeting ADCs after disease progression on targeted therapeutics or immune checkpoint inhibitor therapies

  • Manage patients experiencing adverse events associated with ADCs targeting TROP2, including assessment of physical complaints, radiologic imaging, and lab value interpretation


Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:

Elise Hitron, MSN, FNP-C, has no relevant financial relationships to disclose. 

Srigowri Kota, MSN, BA, APRN, AGNP-C, OCN, has no relevant financial relationships to disclose.

Neelima Vidula, MD: researcher (paid to institution): Daehwa, Merck, Novartis, Pfizer, Radius; consultant/advisor/speaker: Aadi, Gilead, Stemline, TerSera.

The planners and content peer reviewers from Clinical Care Options, LLC do not have any relevant financial relationships to disclose.

Instructions for Credit

Participation in this self-study activity should be completed in approximately 1.25 hours. To successfully complete this activity and receive credit, learners must follow these steps during the period from June 22, 2023, through June 21, 2024:

  1. Login or Sign Up for an account by clicking at the top of this page.
  2. Read the target audience, learning objectives, and faculty disclosures.
  3. View and study the content in its entirety.
  4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the confirmation page. Records of all CME/CE activities completed can be found on the "My Certificates" page. There are no costs/fees for this activity.


This program has been made available online.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.


Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.


Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. 

Nursing Continuing Professional Development

The maximum number of hours awarded for this Nursing Continuing Professional Development activity is 1.25 contact hours.